Micronised progesterone for sleep in transgender wome

Phase 4

• Conditions: Transgender health; Sleep disturbance; Anxiety; Metabolic and Endocrine - Other endocrine disorders; Neurological - Studies of the normal brain and nervous system; Mental Health - Studies of normal psychology, cognitive function and behaviour

• Registration Number: ACTRN12620001364965
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-12-18
• Last Update Posted: 5 January 2021

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Female
• Target Recruitment: 38

Inclusion Criteria

Transfeminine individuals aged 18-70 years.

Exclusion Criteria

1. Contraindications to micronised progesterone.
2. Sunflower seed allergy.
3. Known, suspected, or history of breast cancer.
4. Active deep vein thrombosis, pulmonary embolism or history of these conditions.
5. Active arterial thromboembolic disease or history of these conditions.
6. Known liver dysfunction or disease.
7. Recreational drug use, alcohol dependence, known HIV/AIDS or any disease that is
likely lead to serious illness or death within the study period.
8. Inability to understand sufficient English to provide informed consent or participate in
the trial.

Study & Design

• Study Type: Interventional
• Study Design: Not specified